Inhibition of Ubiquitin Conjugating Enzyme UBE2C Reduces Proliferation and Sensitizes Breast Cancer Cells to Radiation, Doxorubicin, Tamoxifen and Letrozole

Overview

Journal Cell Oncol (Dordr)

Publisher Springer

Date 2013 Sep 28

PMID 24072565

Citations 36

Authors

Akhilesh Rawat

Gopisetty Gopal

Ganesharaja Selvaluxmy

Thangarajan Rajkumar

Affiliations

Soon will be listed here.

Abstract

Purpose: The objective of this study was to determine radiation, doxorubicin, tamoxifen and letrozole sensitivity of breast cancer cells in response to functional inhibition of the ubiquitin conjugating enzyme UBE2C.

Methods: Taqman Real time PCR was performed to measure UBE2C levels in breast cancer cell lines and control HBL100 and HEK293T cells. A dominant negative form of UBE2C (DN-UBE2C) was used to functionally inhibit wild type UBE2C. Cell proliferation and anchorage independent growth were measured by colorimetric and soft agar assays, respectively. Radiation, doxorubicin, tamoxifen and letrozole responses of the cell lines were assessed by colorimetric and clonogenic assays.

Results: Overexpression of UBE2C was observed in all breast cancer cell lines tested using quantitative real time PCR. UBE2C expression was found to be highest in MDAMB231 and relatively lowest in MCF7 cells, compared to control cells. Both the growth rate and the anchorage independent growth of MCF7 and MDAMB231 cells transfected with DN-UBE2C were significantly reduced compared to cells transfected with vector alone. MCF7 and MDAMB231 cells expressing DN-UBE2C were significantly more sensitive to different doses of radiation and doxorubicin compared to both wild type and vector alone transfected cells. In addition, DN-UBE2C transfected MCF7 cells were more sensitive to inhibition by tamoxifen and letrozole compared to wild type and vector alone transfected cells.

Conclusions: Our results show that inhibition of UBE2C sensitizes breast cancer cells to radiation, doxorubicin and hormone blocking agents. UBE2C may, therefore, serve as a potential therapeutic target aimed at inducing radiation and chemo sensitization.

Citing Articles

Ubiquitination-Binding Enzyme 2C is Associated with Cancer Development and Prognosis and is a Potential Therapeutic Target.

Zhao M, Li J, Wang R, Mi L, Gu Y, Chen R Onco Targets Ther. 2024; 17:1159-1171.

PMID: 39678016 PMC: 11637980. DOI: 10.2147/OTT.S485053.

The Chromosome Passenger Complex (CPC) Components and Its Associated Pathways Are Promising Candidates to Differentiate Between Normosensitive and Radiosensitive ATM-Mutated Cells.

Dietz A, Subedi P, Azimzadeh O, Duchrow L, Kaestle F, Paetzold J Biomark Insights. 2024; 19:11772719241274017.

PMID: 39493730 PMC: 11528597. DOI: 10.1177/11772719241274017.

The Abl1 tyrosine kinase is a key player in doxorubicin-induced cardiomyopathy and its p53/p73 cell death mediated signaling differs in atrial and ventricular cardiomyocytes.

Borlak J, Ciribilli Y, Bisio A, Selvaraj S, Inga A, Oh J J Transl Med. 2024; 22(1):845.

PMID: 39285385 PMC: 11403941. DOI: 10.1186/s12967-024-05623-8.

UBE2C promotes the proliferation of acute myeloid leukemia cells through PI3K/AKT activation.

Wang L, Zhao S, Wang Y, Liu J, Wang X BMC Cancer. 2024; 24(1):497.

PMID: 38637730 PMC: 11027220. DOI: 10.1186/s12885-024-12212-x.

The Mechanism of Ubiquitination or Deubiquitination Modifications in Regulating Solid Tumor Radiosensitivity.

Zhang M, Shao Y, Gu W Biomedicines. 2023; 11(12).

PMID: 38137461 PMC: 10741492. DOI: 10.3390/biomedicines11123240.

References

Azzariti A, Porcelli L, Gatti G, Nicolin A, Angelo Paradiso . Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem Pharmacol. 2008; 75(5):1035-44. DOI: 10.1016/j.bcp.2007.11.018. View

Bose M, Gopisetty G, Selvaluxmy G, Rajkumar T . Dominant negative Ubiquitin-conjugating enzyme E2C sensitizes cervical cancer cells to radiation. Int J Radiat Biol. 2012; 88(9):629-34. DOI: 10.3109/09553002.2012.702299. View

Glickman M, Ciechanover A . The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002; 82(2):373-428. DOI: 10.1152/physrev.00027.2001. View

Loussouarn D, Campion L, Leclair F, Campone M, Charbonnel C, Ricolleau G . Validation of UBE2C protein as a prognostic marker in node-positive breast cancer. Br J Cancer. 2009; 101(1):166-73. PMC: 2713693. DOI: 10.1038/sj.bjc.6605122. View

Tfayli A, Temraz S, Mrad R, Shamseddine A . Breast cancer in low- and middle-income countries: an emerging and challenging epidemic. J Oncol. 2011; 2010:490631. PMC: 3010663. DOI: 10.1155/2010/490631. View

Lin J, Raoof D, Wang Z, Lin M, Thomas D, Greenson J . Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia. 2007; 8(12):1062-71. PMC: 1783715. DOI: 10.1593/neo.05832. View

Wagner K, Sapinoso L, El-Rifai W, Frierson H, Butz N, Mestan J . Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene. 2004; 23(39):6621-9. DOI: 10.1038/sj.onc.1207861. View

Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A . UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 2003; 63(14):4167-73. View

Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K . Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer. 2007; 121(1):33-8. DOI: 10.1002/ijc.22605. View

10.

Patel K, Doudican N, Schiff P, Orlow S . Albendazole sensitizes cancer cells to ionizing radiation. Radiat Oncol. 2011; 6:160. PMC: 3231941. DOI: 10.1186/1748-717X-6-160. View

11.

Chada S, Mhashilkar A, Liu Y, Nishikawa T, Bocangel D, Zheng M . mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members. Cancer Gene Ther. 2005; 13(5):490-502. DOI: 10.1038/sj.cgt.7700915. View

12.

Chen S, Chen Y, Hu C, Jing H, Cao Y, Liu X . Association of clinicopathological features with UbcH10 expression in colorectal cancer. J Cancer Res Clin Oncol. 2009; 136(3):419-26. DOI: 10.1007/s00432-009-0672-7. View

13.

Berlingieri M, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G . UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. Oncogene. 2006; 26(14):2136-40. DOI: 10.1038/sj.onc.1210010. View

14.

Townsley F, Aristarkhov A, Beck S, Hershko A, Ruderman J . Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci U S A. 1997; 94(6):2362-7. PMC: 20093. DOI: 10.1073/pnas.94.6.2362. View

15.

Margotto Bertollo C, Rodrigues Correa C, Gomes D, Souza-Fagundes E, Goes A . Effect of radiation treatment on newly established human breast cancer cell lines MACL-1 and MGSO-3. Tumour Biol. 2010; 31(3):189-97. DOI: 10.1007/s13277-010-0029-5. View

16.

Pallante P, Berlingieri M, Troncone G, Kruhoffer M, Orntoft T, Viglietto G . UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br J Cancer. 2005; 93(4):464-71. PMC: 2361574. DOI: 10.1038/sj.bjc.6602721. View

17.

Fujita T, Ikeda H, Kawasaki K, Taira N, Ogasawara Y, Nakagawara A . Clinicopathological relevance of UbcH10 in breast cancer. Cancer Sci. 2008; 100(2):238-48. PMC: 11159056. DOI: 10.1111/j.1349-7006.2008.01026.x. View

18.

Berlingieri M, Pallante P, Sboner A, Barbareschi M, Bianco M, Ferraro A . UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer. 2007; 43(18):2729-35. DOI: 10.1016/j.ejca.2007.09.003. View

19.

Rajkumar T, Sabitha K, Vijayalakshmi N, Shirley S, Bose M, Gopal G . Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer. 2011; 11:80. PMC: 3050856. DOI: 10.1186/1471-2407-11-80. View

20.

Psyrri A, Kalogeras K, Kronenwett R, Wirtz R, Batistatou A, Bournakis E . Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. Ann Oncol. 2011; 23(6):1422-7. DOI: 10.1093/annonc/mdr527. View